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Abstract
Purpose—We investigated under-studied, biomarker-based diabetes among young U.S. adults, 
traditionally characterized by low cardiovascular disease risk.
Methods—We examined 15,701 participants aged 24–32 years at Wave IV of the National 
Longitudinal Study of Adolescent Health (Add Health, 2008). The study used innovative and 
relatively non-invasive methods to collect capillary whole blood via finger prick at in-home 
examinations in all fifty states.
Results—Assays of dried blood spots produced reliable and accurate values of HbA1c. 
Reliability was lower for fasting glucose and lowest for random glucose. Mean (standard 
deviation) HbA1c was 5.6% (0.8%). More than a quarter (27.4%) had HbA1c-defined pre-
diabetes. HbA1c was highest in the black, non-Hispanic race/ethnic group; inversely associated 
with education; and more common among the overweight/obese, and physically inactive. The 
prevalence of diabetes defined by previous diagnosis or use of anti-diabetic medication was 2.9%. 
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Further incorporating HbA1c and glucose values, the prevalence increased to 6.8%, and among 
these participants, 38.9% had a previous diagnosis of diabetes (i.e., aware). Among those aware, 
37.6% were treated and 64.0% were controlled (i.e., HbA1c < 7%).
Conclusions—A contemporary cohort of young adults faces a historically high risk of diabetes 
but there is ample opportunity for early detection and intervention.
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In 2012, economic costs of diagnosed diabetes totaled $245 billion, including $176 billion in 
direct medical costs and $69 billion in reduced productivity (1). The 2012 economic burden 
represents a 41% increase from $174 billion in 2007. The largest components of medical 
expenditures for diabetes include hospital inpatient care (43%) and prescription medications 
for diabetes complications (18%). Type 2 diabetes onset at age 20 is associated with a 15-
year reduction in life expectancy, increased risk of severe, chronic diabetes complications by 
age 40, and worse education attainment and employment outcomes (2, 3). As such, diabetes 
in the first few decades of life is clinically, economically and societally burdensome (3–6).
However, little is known about diabetes prevalence in contemporary populations of young 
adults in the United States, traditionally characterized by low cardiovascular disease risk. 
Given that 28% of the US population is unaware of their diabetes, exam-based assessments 
such as those from the National Health and Nutrition Examination Survey (NHANES) 
provide valuable information on the full burden of diabetes (7–10). Besides NHANES, to 
our knowledge, the National Longitudinal Study of Adolescent Health (Add Health) is the 
only other study from which it is possible to estimate biomarker-based prevalence of 
diabetes among contemporary U.S. young adults in their twenties.
Add Health—widely used in social, behavioral, and health science research (11)—is notable 
for its national probability sampling strategy, oversampling of typically underrepresented 
groups, and high response rate. Add Health is uniquely suited for examinations of the 
transition to adulthood. The larger sample of young adults (15–20 times the size of one 
NHANES cohort of young adults) enables potentially more precise estimates and 
comprehensive analysis of subgroup differences (e.g., incorporating finer racial/ethnic 
categorizations) (12–14). Additionally, the measurement of diabetes in field studies such as 
Add Health is distinct from and potentially more complicated than that in examination 
center-based studies, requiring adaptation of biomarker collection to more variable home 
environments and utilizing many more field staff.
In Add Health, measures of glucose homeostasis were obtained via an innovative and 
relatively non-invasive collection of capillary whole blood via finger prick. While these 
relatively recently developed methods of evaluating glucose homeostasis have been used in 
the Moving to Opportunity (MTO) housing experiment, Health and Retirement Study 
(HRS), National Social Life, Health, and Aging Project (NSHAP), and Los Angeles Family 
and Neighborhood Survey (LAFANS), little information is available on the validity and 
reliability of the measurements they generate (15–17). We therefore examined these 
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properties in the larger Add Health sample. Addressing gaps in the literature, the objectives 
of this study are to: first assess the quality of measures of glucose homeostasis derived from 
dried blood spot technology, and then to quantify diabetes prevalence overall and by 
important demographic, social, clinical and behavioral risk factors, thereby allowing 
assessments of health disparities.
METHODS
Add Health study design and data collection
Add Health enrolled a national probability sample of 20,745 U.S. adolescents in grades 7 
through 12 during the 1994–1995 school year (Wave I response rate: 79%) (18). The Add 
Health cohort has been followed for over a 13-year period and represents over 22 million 
individuals. Three in-home follow-up interviews have been completed: Wave II in 1996 
(88% of the eligible cohort at Wave I), Wave III in 2001–2002 (77%), and Wave IV in 2008 
(80%). Each wave of the study was approved by the University of North Carolina Public 
Health-Nursing Institutional Review Board (Chapel Hill, NC).
Detailed information on Add Health’s measures of glucose homeostasis has been published 
elsewhere (19). Briefly, all 15,701 Wave IV Add Health participants were asked whether a 
health care professional ever told them they had high blood sugar or diabetes (i.e., self-
reported history of diabetes). Women were asked to exclude diagnoses during pregnancy. 
Anti-diabetic medication use within the preceding four weeks was inventoried by visually 
inspecting participant-assembled medication containers and categorizing their contents in 
real-time using Lexicon Plus™ (Lexi-Comp®, Inc.; Hudson, OH).
Capillary whole blood was collected via finger prick from voluntarily fasting (≥8 hours) and 
non-fasting participants onto seven-spot, Whatman 903® Protein Saver cards by trained and 
certified field interviewers, subjected to in situ desiccation, then shipped to FlexSite 
Diagnostics, Inc. (Palm City, FL) for assay of HbA1c (%), and to the University of 
Washington Department of Laboratory Medicine (Seattle, WA) for assay of glucose (mg/dl). 
The analytical sensitivity, within- and between-assay coefficients of variation were 3.0%, 
2.2% and 2.4% for HbA1c and 22 mg/dl, 4.4%, and 4.8% for glucose. In paired whole blood 
and blood spots (n=80), HbA1c values were strongly associated (Pearson r = 0.99). 
Associations in paired serum and blood spots (n=83) were equally strong for glucose 
concentrations (Pearson r = 0.97).
Test-retest reliability analysis in Add Health—In a quality control study conducted 
over the course of field work, the short-term retest reliability of HbA1c and glucose was 
assessed in a race/ethnicity- and sex-stratified random sample of 100 Add Health Wave IV 
participants (mean age 29 years; 50% female; 64% non-Hispanic White; 16 % non-Hispanic 
Black; 12 % Hispanic/Latino; 8 % other) examined twice, one to two weeks (mean: 8.6 
days) apart. At the two examinations, biospecimens were collected typically by the same 
field interviewer (84% of participants) and at approximately the same time of day (mean |
difference|: 52 minutes; range 0–302 minutes).
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The variance in measures of HbA1c (and separately, glucose) was partitioned in a random 
effects model by letting Yij be the measure on the ith participant at the jth visit: Yij=μ
+Pi+mj(i)+eij, where μ is the sample mean and Pi, mj(i), and eij are the normally distributed 
participant, measurement, and error effects with mean zero and variance , and , 
respectively. Assuming the variance components are independently distributed, the total 
variance of  is: . Reliability was then estimated as the ratio of the 
between-participant to total variance: , i.e. an intraclass correlation coefficient (ICC) 
with 95% confidence intervals estimated using the delta method (20). The ICC represents 
the proportion of variance not due to measurement variance. Random effects models were 
implemented in SAS® 9.1 using Proc Mixed and the restricted maximum likelihood 
method.
Validity analysis in Add Health—In a separate quality control study conducted over ten 
weeks of field work, a dried blood spot (DBS) from each of three donors was shipped twice 
weekly to FlexSite Diagnostics, Inc. (“Lab A”) and assayed by laboratory staff masked to 
the origin of the samples. The 60 returned values of HbA1c were compared to values of 
HbA1c conventionally assayed in paired whole blood from the same donors on a G7 
Automated HPLC-HbA1c Analyzer (Tosoh Bioscience, Inc., San Francisco, CA) by Duke 
University Health System Laboratories (Durham, NC) (“Lab B”). Accuracy was computed 
as the Lab A minus Lab B difference (bias, %) and its ratio with respect to the criterion 
standard (relative bias = 100 × bias/Lab B).
Identification of diabetes and its medical management
Diabetes was identified by incorporating self-reported history, anti-diabetic medication use, 
and abnormality of HbA1c and/or glucose identified by American Diabetes Association 
(ADA) diagnostic thresholds (21): (1) HbA1c ≥ 6.5 %, (2) non-fasting glucose ≥ 200 mg/dl, 
and/or (3) fasting glucose ≥ 126 mg/dl. Pre-diabetes (HbA1c = 5.7–6.4%) also was 
identified. Among those with diabetes, awareness was defined as reporting a previous 
diagnosis. Among those aware, treatment was defined as taking anti-diabetic medications 
and control of diabetes was defined as HbA1c <7%, according to ADA guidelines (22).
Covariates—Subgroups were defined by the following characteristics: sex (male, female), 
race/ethnicity (non-Hispanic whites, blacks, and Asian/Pacific Islanders, other race/
multiracial, Mexican-American, other Hispanic), education (0–11 years, high school 
graduate/GED, some college/Associate’s degree, 4-year college) as well as foreign birth, 
insurance status, history of diabetes, use of anti-diabetic medication, and fasting ≥ 8 hours. 
Body mass index (BMI kg/m2) categories included: underweight/normal (<18.5–24.9); 
overweight (25.0–29.9); obese class I (30–34.9): obese class II/III (≥ 35.0). Central obesity 
was defined as waist circumference > 102 cm (men) or > 88 cm (women, excluding 
pregnant women) (23). Fast food intake was assessed via past-7 day frequency of eating 
from a fast food restaurant (0, ≤ 2 times, ≥3 times). Binge drinking was assessed via 
frequency of ≥ 5 (men) or ≥ 4 (women) drinks in a row (none, less than weekly, weekly). 
Cigarette smoking was assessed by past-30 day smoking frequency (none, less than daily, 
daily) (24–26). Moderate to vigorous recreational physical activity was defined as the 
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number of times in the past seven days participants engaged in various physical activities (≥ 
5 times, 1–4 times, none) (27), assessed by summing responses to seven questions (e.g., “In 
the past seven days, how many times did you roller blade, roller skate, downhill ski, snow 
board, play racquet sports, or do aerobics?”). Measurement session was categorized as 
morning (8:30am), afternoon (1:30pm), and evening (5:30pm).
Analyses of HbA1c and glucose utilized data from 13,465 and 13,112 participants aged 24–
32 years with non-missing survey weights and assay results. Summary statistics were 
estimated using STATA®/SE 10 software (StataCorp LP, College Station, TX), accounting 
for the clustered design and using sample weights to adjust for unequal probability of 
selection and attrition, to produce nationally representative estimates.
RESULTS
In our analysis sample, the mean age of participants was 28 years and approximately half 
were female (Table 1). Two-thirds were white, with large proportions of blacks (14%) and 
Hispanics (11%). Results of our quality control studies suggest reliability was highest for 
HbA1c (ICC: 0.97), lower for fasting glucose (ICC: 0.66), and lowest for random glucose 
collected in the fasting or non-fasting state (ICC: 0.39) (Table 2). Within-participant 
coefficients of variation were 2.4% for HbA1c, 13.5% for fasting glucose, and 17.5% for 
random glucose (Table 2). HbA1c was over-estimated by an average of 0.2% in dried blood 
spot testing compared to conventional whole blood assays, but relative bias did not exceed 
5% (Table 3).
The prevalence of HbA1c-defined diabetes was 3.6%. More than a quarter (27.4%) had 
HbA1c-defined pre-diabetes (Table 4). HbA1c was highest in the black, non-Hispanic race/
ethnic group; inversely associated with education; and more common among participants 
with a history of diabetes or elevated fasting glucose, users of anti-diabetic medication, the 
overweight/obese, and the physically inactive. Participants were not asked to fast, and only 
16% fasted. Among fasters, racial/ethnic minorities, obesity, history of diabetes, and use of 
anti-diabetic medications were over-represented when compared to the entire population 
(not shown). Therefore prevalence of non-fasting glucose ≥ 200 mg/dl or fasting glucose ≥ 
126 mg/dl was estimated: 2.5%, overall (Table 5). Discernible patterns of variation in 
glucose with participant characteristics reflected those of HbA1c, described above. Overall, 
5.1% had either high HbA1c or high glucose (i.e., HbA1c ≥ 6.5, fasting glucose ≥ 126 
mg/dl, or non-fasting glucose ≥ 200 mg/dl) and among these participants, only 24.0% 
reported a previous diagnosis of diabetes.
The prevalence of diabetes defined by previous diagnosis or use of anti-diabetic medication 
was 2.9% (95% CI: 2.5, 3.3) (Table 6). Further incorporating HbA1c and glucose values, the 
prevalence increased to 6.8%, and among these, 38.9% had a previous diagnosis of diabetes 
(i.e., aware). Among those aware, 37.6% were taking anti-diabetic medication (i.e., treated), 
and 64.0% had HbA1c < 7% (i.e., controlled).
Supplemental analyses compared diabetes prevalence in Add Health with similarly aged 
adults (24–32 years) in NHANES 2007–2008 (see Appendix A for details on NHANES 
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study design and cross-survey analyses). In NHANES, prevalence of diabetes incorporating 
self-reported history, anti-diabetic medication use, fasting glucose and HbA1c was 2.6% 
(n=294). Compared with NHANES, participants in Add Health were less likely to be 
foreign-born, uninsured, and have less than a high school education, and more likely to be 
obese (not shown). Between survey differences were attenuated after controlling for age, 
sex, race/ethnicity, foreign-birth, education, health insurance, BMI status, central obesity, 
fast food intake, physical activity, cigarette use, and heavy drinking; Add Health vs. 
NHANES adjusted risk ratio: 1.7 (95% CI: 0.8, 3.7).
DISCUSSION
We investigated the under-studied, biomarker-based prevalence of diabetes in a 
contemporary cohort of young U.S. adults by collecting capillary whole blood via finger 
prick and assaying HbA1c and glucose in dried blood spots (28). To put results in context, 
fasting plasma glucose has greater biological variability compared to HbA1c with 
coefficients of variation (CV) between 5–8% vs. 1–2%, respectively (29–31). Given 
biological variability, laboratory quality management standards designed to support 
informed medical decision-making suggest glucose analyses have desired analytic 
imprecision ≤ 2.3%, bias ≤ 1.8%, and total error ≤ 5.5% and that HbA1c (%) analyses have 
imprecision, bias and total error ≤ 0.9%, 1.5%, and 3.0%, respectively (32). In this study, we 
found that HbA1c values were highly reliable, minimally biased, and strongly correlated 
with fasting glucose. Analytic imprecision and bias of dried blood spot HbA1c 
approximated targeted analytic specifications derived from conventional clinical assays. 
Variability of glucose values from DBS slightly exceeded the range of previously reported 
estimates from conventional clinical analyses (33–35). However, glucose varied strikingly 
with participant characteristics related to well-known glucohomeostatic abnormalities, 
regardless of fasting status, and in doing so, mirrored blood spot-based HbA1c.
Next, we then turned to the identification of diabetes. The prevalence of HbA1c-defined pre-
diabetes and diabetes was 27.4 and 3.6%. After incorporating history of diabetes, anti-
diabetic medications, high HbA1c, and high glucose, diabetes prevalence increased to 6.8%, 
with only 38.9% reporting a previous diagnosis of diabetes (i.e., aware). Among those 
aware, 37.6% were treated with medications and 64.0% were controlled.
Study findings in context
In recent decades, minorities and economically disadvantaged groups have experienced the 
greatest rise in diabetes and worst outcomes from this disease (36–39). Between-group 
disparities in diabetes among young adults align with those found for all U.S adults. Age-
standardized diabetes prevalence is higher among non-Hispanic blacks, Hispanics, and those 
of other/mixed races compared to Asians and non-Hispanic whites. Diabetes is also 
inversely correlated with education and income (40).
Typically studies utilizing dried blood spots technology to identify diabetes are conducted 
among populations of older adults. For instance, in the 2006 Health and Retirement Study of 
adults over the age of 50, diabetes (HbA1c ≥6.5%) prevalence was 33% among blacks, 37% 
among Hispanics, and 17% among whites (41). Comparable prevalence estimates are 
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uncommon for younger U.S. adults at the forefront of the obesity epidemic. Moreover, 
diabetes is just one of many comorbidities that collectively foreshadow a future epidemic of 
chronic diseases among young people as they age (42–46). In Add Health among young 
adults, the prevalence of hypertension and obesity was 19% and 36%, respectively (47, 48).
Study strengths and limitations
In a nationally representative field study, we investigated the quality of measures of glucose 
homeostasis and the prevalence of diabetes among young U.S. adults, traditionally 
characterized by low chronic disease risk. The study used innovative, cost-efficient, and 
relatively non-invasive methods to collect capillary whole blood via finger prick at in-home 
examinations in all fifty states. Add Health’s in-home collection of biomarkers at Wave IV 
enables researchers to study what appear to be rising rates of chronic diseases among 
younger-aged groups in the United States (44–47). Moreover, reliable estimates of disease 
can be produced in Add Health for many groups underrepresented in other surveys.
However, our study has some limitations. Attrition may be of concern. Females, whites, and 
those with higher SES had higher response rates at Wave IV. Nonetheless, non-response 
biases are small across diverse measures of demographic characteristics, health and risk 
behaviors (49). Moreover, non-response at Wave IV was neither associated with risk of pre-
diabetes nor undiagnosed diabetes predicted from demographic characteristics, SES, health 
behaviors, and health status (unpublished results, Anna Bellatorre, University of Nebraska). 
Importantly, in our analyses, we utilized survey weights to adjust for attrition.
The lack of a fasting requirement in Add Health meant that fasting glucose was available for 
only a non-representative subset of participants. A random glucose cut-point of 200 mg/dl is 
endorsed by the ADA for diabetes diagnosis and widely used in cohort studies such as the 
Framingham Heart Study and ARIC study (22, 50–52). However, it may have lower 
sensitivity than other detection methods. For example, previous studies found that random 
glucose values ≥ 160 mg/dl had a sensitivity of 44% and specificity of 96% (8) compared to 
fasting glucose ≥ 120 mg/dl which had a sensitivity of 67% specificity of 98%, and HbA1c 
≥ 6.3% which had sensitivity of 40% sensitivity and specificity of 98% (53). Some have 
proposed utilizing random glucose to enable cost-efficient opportunistic screening of 
diabetes (54, 55). A study of a large health care system found that 70% of patients had a 
measure of glycemia in the past 3 years and 95% of these measurements were random 
glucose—likely due to routine inclusion of random glucose in standard chemistry panels 
(56). Alternatively, in this study, reliability of HbA1c was excellent and prevalence of 
diabetes estimated by HbA1c ≥ 6.5% was available in both fasting and non-fasting 
populations. Advantages of HbA1c in identifying diabetes include convenience (no fasting 
requirement), greater pre-analytic stability, and ability to integrate exposure to 
hyperglycemia over the prior 2–3 months (57, 58). However, HbA1c may have lower 
sensitivity than fasting glucose (59, 60). Also, guidelines for identifying diabetes 
recommend basing diagnoses on repeat testing, an approach unavailable in this research 
study (21).
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Diabetes is a growing problem in the United States with one study projecting that as many 
as one-third of adults could have diabetes in 2050 if trends persist (61). Low awareness of 
diabetes and the alarming rate of pre-diabetes among young adults suggest ample 
opportunity for early detection and intervention in a population often assumed to be 
unburdened by chronic conditions. National data from Add Health suggest that this cohort of 
young adults faces a historically high risk of cardiovascular disease, with higher than 
expected burden of diabetes as well as hypertension and obesity (47, 48). This finding is 
important because it may portend exponential growth in health issues and health care costs. 
Tackling disparities in the burden of chronic diseases, already apparent among young adults, 
is a critical endeavor.
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Table 1
Characteristics of the Add Health Wave IV (2008) Participants Aged 24–32 years
na % (95% CI)b
Age, Mean(SD) 13542 28.3 (1.8)
Females 7315 50.2 (48.9, 51.4)
Race/Ethnicity
 White, Non-Hispanic 7307 66.6 (60.8, 72.0)
 Black, Non-Hispanic 2643 14.3 (10.9, 18.6)
 Asian/Pacific Islander, non-Hispanic 748 2.9 (1.8, 4.6)
 Other Race/Multiracial 828 5.1 (4.3, 6.1)
 Mexican-American 908 5.9 (4.1, 8.6)
 Other Hispanic 1053 5.1 (3.5, 7.5)
Nativity
 U.S. Born 12541 94.8 (92.9, 96.1)
 Foreign-Born 995 5.3 (3.9, 7.1)
Education
 4-yr college or greater 4218 29.4 (26.3, 32.6)
 Some college/AA degree 6073 43.8 (42.1, 45.4)
 H.S. graduate/GED 2201 17.8 (16.1, 19.6)
 0–11 years 1049 9.0 (7.8, 10.5)
Uninsured 2817 22.4 (21.0, 23.8)
Currently pregnant (among females) 455 3.0 (2.7, 3.4)
History of diabetes 392 2.6 (2.3, 3.1)
Diabetes medications 194 1.3 (1.1, 1.6)
Fasting ≥ 8 hours 2221 16.3 (15.1, 17.7)
BMI
 Underweight/Normal 4225 33.1 (31.6, 34.7)
 Overweight 3848 29.4 (28.2, 30.6)
 Obese Class I 2391 18.7 (17.7, 19.6)
 Obese Class II/III 2475 18.8 (17.6, 20.2)
Abdominal obesityc 6397 48.1 (46.5, 49.8)
Fast food intake (times a week)
 None 3084 23.3 (21.4, 25.3)
 2 or less 5854 43.1 (41.9, 44.3)
 3 or more 4596 33.6 (31.6, 35.6)
Moderate to vigorous recreational activity
 5+ times a week 7196 53.4 (51.9, 54.9)
 1–4 times/week 4242 31.9 (30.8, 33.0)
 None 2094 14.7 (13.7, 15.7)
Smoking
 None in past 30 days 8575 60.8 (58.8, 62.7)
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na % (95% CI)b
 Less than Daily 1900 14.1 (13.3, 15.1)
 Daily 2957 25.1 (23.2, 27.1)
Binge drinking
 None 7121 49.8 (47.6, 52.0)
 < Weekly 4857 37.9 (36.1, 39.7)
 ≥ Weekly 1515 12.4 (11.3, 13.5)
Measurement session
 Morning 6075 45.1 (43.5, 46.7)
 Afternoon 4239 32.1 (31.0, 33.2)
 Evening 3167 22.9 (21.5, 24.3)
a
Restricted to participants with HbA1c or glucose data
b
Percentages (95% confidence interval) weighted to be representative of U.S. adolescents in grades 7–12 during the 1994–1995 school year
c
Abdominal obesity defined as > 102 cm (men) and > 88 cm (women, excluding pregnant women)
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Table 5
High Glucose (mg/dL) Prevalence by Participant Characteristics
Characteristic Subgroup n
Non-Fasting Glucose ≥ 200 or Fasting Glucose ≥ 126 mg/dl
% (95% CI)a
Overall 13112 2.5 (2.2, 2.9)
Sex Males 5972 3.5 (2.9, 4.2)
Females 7140 1.6 (1.2, 2.2)
Race/Ethnicity White, non-Hispanic 7092 2.0 (1.7, 2.5)
Black, non-Hispanic 2518 3.4 (2.5, 4.7)
Asian/Pacific Islander, non-Hispanic 739 1.2 (0.5, 2.7)
Other Race/Multiracial 808 4.2 (2.1, 8.3)
Mexican 881 4.2 (2.4, 7.3)
Other Hispanic 1019 3.6 (2.3, 5.4)
Nativity U.S. Born 12319 2.5 (2.1, 2.9)
Foreign-Born 792 1.9 (0.9, 4.0)
Education 4-yr college or greater 4096 1.5 (1.0, 2.2)
Some college/AA degree 5883 2.8 (2.3, 3.4)
H.S. graduate/GED 2120 3.1 (2.1, 4.6)
0–11 years 1013 3.5 (2.3, 5.2)
Uninsured No 10374 2.3 (1.9, 2.8)
Yes 2720 3.3 (2.5, 4.5)
Currently pregnant No 12664 2.6 (2.2, 3.0)
Yes 448 1.2 (0.4, 3.4)
History of diabetes No 12728 1.8 (1.5, 2.2)
Yes 383 27.8 (22.2, 34.2)
Diabetes medications No 12923 2.0 (1.7, 2.4)
Yes 189 38.0 (29.8, 47.0)
Fasting ≥ 8 hours Yes 2221 10.3 (8.6, 12.2)
No 10778 1.0 (0.7, 1.3)
HbA1c (%) ≤ 5.6 8674 1.0 (0.7, 1.4)
5.7–6.4 3790 2.5 (1.9, 3.3)
≥ 6.5 570 31.6 (25.1, 38.8)
BMI Underweight/Normal 4069 1.4 (1.0, 1.9)
Overweight 3715 1.9 (1.3, 2.7)
Obese Class I 2324 3.0 (2.1, 4.1)
Obese Class II/III 2413 5.2 (4.0, 6.7)
Central obesityb No 6377 1.7 (1.3, 2.2)
Yes 6226 3.4 (2.8, 4.2)
Fast food intake per week None 2987 2.0 (1.5, 2.8)
2 or less 5678 2.3 (1.8, 3.0)
3 or more 4439 3.1 (2.5, 3.9)
Recreational activity 5+ times a week 6954 2.0 (1.6, 2.6)
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Characteristic Subgroup n
Non-Fasting Glucose ≥ 200 or Fasting Glucose ≥ 126 mg/dl
% (95% CI)a
1–4 times/week 4131 2.9 (2.3, 3.6)
None 2016 3.6 (2.6, 4.9)
Smoking None in past 30 days 8301 2.6 (2.1, 3.2)
< Daily 1834 2.3 (1.6, 3.4)
Daily 2873 2.4 (1.8, 3.3)
Binge drinking None 6896 2.7 (2.2, 3.3)
< Weekly 4715 2.1 (1.6, 2.8)
≥ Weekly 1456 2.9 (1.8, 4.8)
a
Weighted to be representative of U.S. adolescents in grades 7–12 during the 1994–1995 school year
b
Abdominal obesity defined as > 102 cm (men) and > 88 cm (women, excluding pregnant women)
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Table 6
Diabetes and Its Medical Management
Diabetes definition N % (95% CI)
Self-report and medication inventory
 Medication useb 14751 1.3 (1.0, 1.6)
 Historyc 14749 2.6 (2.2, 3.0)
 History or medication 14749 2.9 (2.5, 3.3)
HbA1c, self-report, medication inventory
 Highd HbA1c 13465 3.6 (3.0, 4.4)
 Highd HbA1c, history or medication 13464 5.4 (4.7, 6.3)
Glucose, self-report, medication inventory
 Highd glucose 13111 2.5 (2.2, 2.9)
 Highd glucose, history or medication 13111 4.8 (4.3, 5.3)
Comprehensive
 Diabetes (High glucose, high HbA1c, history or medication) 13034 6.8 (6.0, 7.7)
Medical management
 Among those with diabetes, percent aware (i.e., diagnosed) 972 38.9 (33.8, 44.3)
 Among those aware, percent treated with medications 383 37.6 (30.4, 45.5)
 Among those aware, percent controlled (i.e., HbA1c < 7%) 383 64.0 (56.9, 70.5)
Missingness varies due to availability of variables used to define diabetes
a




History of being told by a doctor or healthcare professional that you have diabetes (if female, outside of pregnancy).
d
For HbA1c, non-fasting glucose, and fasting glucose: ≥ 6.5%, 200 mg/dl and 126 mg/dl, respectively
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